A-1282576.0 OR ABT-493 OR Glecaprevir - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 1803

<< First< Prev

Page of 91

Next >Last >>

The following term was not found in PMC: 1282576.0.

Select item 57403811.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

Teresa I. Ng, Rakesh Tripathi, Thomas Reisch, Liangjun Lu, Timothy Middleton, Todd A. Hopkins, Ron Pithawalla, Michelle Irvin, Tatyana Dekhtyar, Preethi Krishnan, Gretja Schnell, Jill Beyer, Keith F. McDaniel, Jun Ma, Guoqiang Wang, Li-Juan Jiang, Yat Sun Or, Dale Kempf, Tami Pilot-Matias, Christine Collins

Antimicrob Agents Chemother. 2018 Jan; 62(1): e01620-17. Prepublished online 2017 Oct 30. Published online 2017 Dec 21. doi: 10.1128/AAC.01620-17

PMCID:: PMC5740381

Article PDF–455K

Select item 56104902.

No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir

Matthew P. Kosloski, Weihan Zhao, Armen Asatryan, Jens Kort, Pierre Geoffroy, Wei Liu

Antimicrob Agents Chemother. 2017 Oct; 61(10): e00958-17. Prepublished online 2017 Aug 14. Published online 2017 Sep 22. doi: 10.1128/AAC.00958-17

PMCID:: PMC5610490

Article PDF–974K

Select item 63145653.

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

Graham R. Foster, Tarik Asselah, Sarah Kopecky-Bromberg, Yang Lei, Armen Asatryan, Roger Trinh, Neddie Zadeikis, Federico J. Mensa

PLoS One. 2019; 14(1): e0208506. Published online 2019 Jan 2. doi: 10.1371/journal.pone.0208506

PMCID:: PMC6314565

Article PDF–900K

Select item 90984624.

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment

Hironao Okubo, Masanori Atsukawa, Tomomi Okubo, Hitoshi Ando, Eisuke Nakadera, Kenichi Ikejima, Akihito Nagahara

Sci Rep. 2022; 12: 7847. Published online 2022 May 12. doi: 10.1038/s41598-022-11707-6

PMCID:: PMC9098462

Article PDF–1.1M

Select item 58261285.

Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects

Matthew P. Kosloski, Weihan Zhao, Thomas C. Marbury, Richard A. Preston, Michael G. Collins, David Pugatch, Federico Mensa, Jens Kort, Wei Liu

Antimicrob Agents Chemother. 2018 Mar; 62(3): e01990-17. Prepublished online 2017 Dec 20. Published online 2018 Feb 23. doi: 10.1128/AAC.01990-17

PMCID:: PMC5826128

Article PDF–796K

Select item 62208746.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown, Jr, Kosh Agarwal, Peter Angus, Edward Gane, Jia‐Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns

Hepatology. 2018 Oct; 68(4): 1298–1307. Published online 2018 Jul 25. doi: 10.1002/hep.30046

PMCID:: PMC6220874

Article PDF–471K

Select item 57867937.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Bo Fu, Margaret Burroughs, Rebecca Redman, Hiromitsu Kumada, Kazuaki Chayama, Christine Collins, Tami Pilot-Matias

Antimicrob Agents Chemother. 2018 Feb; 62(2): e02217-17. Prepublished online 2017 Nov 27. Published online 2018 Jan 25. doi: 10.1128/AAC.02217-17

PMCID:: PMC5786793

Article PDF–510K

Select item 61719338.

Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir

Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Liangjun Lu, Teresa I. Ng, Wangang Xie, Tami Pilot-Matias, Christine Collins

PLoS One. 2018; 13(10): e0205186. Published online 2018 Oct 4. doi: 10.1371/journal.pone.0205186

PMCID:: PMC6171933

Article PDF–6.8M

Select item 80778349.

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Machiko Umemura, Goki Suda, Shihori Tsukamoto, Ko Ebata, Shinjiro Takahash, Takashi Sasaki, Sae Nakajima, Koji Hirata, Mariko Ozasa, Masatoshi Takano, Masaki Katagiri, Naoya Sakamoto

BMC Infect Dis. 2021; 21: 389. Published online 2021 Apr 27. doi: 10.1186/s12879-021-06091-x

PMCID:: PMC8077834

Article PDF–405K

Select item 477594510.

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

Eric J. Lawitz, William D. O'Riordan, Armen Asatryan, Bradley L. Freilich, Terry D. Box, J. Scott Overcash, Sandra Lovell, Teresa I. Ng, Wei Liu, Andrew Campbell, Chih-Wei Lin, Betty Yao, Jens Kort

Antimicrob Agents Chemother. 2016 Mar; 60(3): 1546–1555. Prepublished online 2015 Dec 28. Published online 2016 Feb 26. doi: 10.1128/AAC.02264-15

PMCID:: PMC4775945

Article PDF–1.2M

Select item 668115411.

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Thomas G Cotter, Donald M Jensen

Drug Des Devel Ther. 2019; 13: 2565–2577. Published online 2019 Jul 29. doi: 10.2147/DDDT.S172512

PMCID:: PMC6681154

Article PDF–1.3M

Select item 737973512.

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Steven Flamm, David Mutimer, Armen Asatryan, Stanley Wang, Jürgen Rockstroh, Yves Horsmans, Paul Y. Kwo, Ola Weiland, Erica Villa, Jeong Heo, Edward Gane, Stephen D. Ryder, Tania M. Welzel, Peter J. Ruane, Kosh Agarwal, Teresa I. Ng, Zhenyi Xue, Sandra S. Lovell, Preethi Krishnan, Sarah Kopecky‐Bromberg, Roger Trinh, Federico J. Mensa, David L. Wyles

J Viral Hepat. 2019 Mar; 26(3): 337–349. Published online 2018 Dec 11. doi: 10.1111/jvh.13038

PMCID:: PMC7379735

Article PDF–598K

Select item 744439913.

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Pietro Lampertico, Stefan Mauss, Marcello Persico, Stephen T. Barclay, Steven Marx, Kristina Lohmann, Mark Bondin, ZhenZhen Zhang, Fiona Marra, Pamela S. Belperio, Heiner Wedemeyer, Steven Flamm

Adv Ther. 2020; 37(9): 4033–4042. Published online 2020 Aug 4. doi: 10.1007/s12325-020-01449-0

Correction in:: Adv Ther. 2020; 37(11): 4755–4756.

PMCID:: PMC7444399

Article PDF–440K

Select item 812966814.

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution

Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho

Gut Liver. 2021 May 15; 15(3): 440–450. Published online 2020 Aug 26. doi: 10.5009/gnl19393

PMCID:: PMC8129668

Article PDF–424K

Select item 764155115.

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen

Clin Mol Hepatol. 2020 Oct; 26(4): 554–561. Published online 2020 Aug 28. doi: 10.3350/cmh.2020.0058

PMCID:: PMC7641551

Article PDF–841K

Select item 774706116.

Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir

Jennifer Timm, Klajdi Kosovrasti, Mina Henes, Florian Leidner, Shurong Hou, Akbar Ali, Nese Kurt-Yilmaz, Celia A. Schiffer

ACS Chem Biol. Author manuscript; available in PMC 2020 Dec 18.

Published in final edited form as: ACS Chem Biol. 2020 Feb 21; 15(2): 342–352. Published online 2020 Jan 8. doi: 10.1021/acschembio.9b00675

PMCID:: PMC7747061

Article PDF–1.8M

Select item 718717017.

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials

Ashley Brown, Tania M. Welzel, Brian Conway, Francesco Negro, Norbert Bräu, Jason Grebely, Massimo Puoti, Alessio Aghemo, Henning Kleine, David Pugatch, Federico J. Mensa, Yaozhu J. Chen, Yang Lei, Eric Lawitz, Tarik Asselah

Liver Int. 2020 Apr; 40(4): 778–786. Published online 2019 Oct 18. doi: 10.1111/liv.14266

PMCID:: PMC7187170

Article PDF–558K

Select item 726826118.

Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy

Anas Shamsi, Taj Mohammad, Saleha Anwar, Mohamed F. AlAjmi, Afzal Hussain, Md. Tabish Rehman, Asimul Islam, Md. Imtaiyaz Hassan

Biosci Rep. 2020 Jun 26; 40(6): BSR20201256. Published online 2020 Jun 2. doi: 10.1042/BSR20201256

PMCID:: PMC7268261

Article PDF–1.0M

Select item 643609919.

Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy

Ameer Abutaleb, Shyam Kottilil, Eleanor Wilson

Hepatol Int. Author manuscript; available in PMC 2019 May 29.

Published in final edited form as: Hepatol Int. 2018 May; 12(3): 214–222. Published online 2018 May 29. doi: 10.1007/s12072-018-9873-y

PMCID:: PMC6436099

Article PDF–99K

Select item 682122020.

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

Edward Gane, Fred Poordad, Neddie Zadeikis, Joaquin Valdes, Chih-Wei Lin, Wei Liu, Armen Asatryan, Stanley Wang, Catherine Stedman, Susan Greenbloom, Tuan Nguyen, Magdy Elkhashab, Marcus-Alexander Wörns, Albert Tran, Jean-Pierre Mulkay, Carolyn Setze, Yao Yu, Tami Pilot-Matias, Ariel Porcalla, Federico J Mensa

Clin Infect Dis. 2019 Nov 15; 69(10): 1657–1664. Published online 2019 Mar 28. doi: 10.1093/cid/ciz022

PMCID:: PMC6821220

Article PDF–221K

<< First< Prev

Page of 91

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

Find related data

Search details

Recent activity

Clear Turn Off Turn On

A-1282576.0 OR ABT-493 OR Glecaprevir (1803)
PMC

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to: